Navigation Links
Norgine and Innovacell Enter Into an Exclusive Licensing Agreement for ICEF15 - An Innovative Personalised Cell Therapy to Treat Faecal Incontinence
Date:12/17/2013

LONDON, December 17, 2013 /PRNewswire/ --

Norgine B.V. ("Norgine") and Innovacell today announced they have entered into an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15. Innovacell and Norgine will co-develop ICEF15 and Norgine will commercialise the product. The start of the ICEF15 phase IIb clinical trial is imminent and it is anticipated that the first patient will be dosed in Q1 2014.

     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a)

     (Photo: http://photos.prnewswire.com/prnh/20131213/659040 )

ICEF15 is developed for both men and women suffering from faecal incontinence with sphincter weakness or damage. ICEF15 is a personalised cell-based product concept based upon proliferating autologous myoblasts from a biopsy taken from the patients' own muscle. The patient's proliferated muscle cells are re-injected into the patient's external anal sphincter muscle, using Innovacell's proprietary injection device, thereby regenerating the muscle´s full functionality.

Phase I/II clinical trial data have shown a rapid reduction in the symptoms of faecal incontinence as well as an improvement in the quality of life. In addition, data from a retrospective study (5 years - post treatment) show that ICEF15 has a lasting effect.

It is estimated that in major European countries, around 5 per cent of all adult men and women will suffer from faecal incontinence.

Ekkehart Steinhuber, CEO at Innovacell, said, "By partnering with Norgine, Innovacell is accessing demonstrated gastroenterology and commercial expertise and capabilities that will accelerate development and market entry of ICEF15 in Europe, SADAC and MENA. ICEF15 could help many patients to overcome faecal incontinence, a very debilitating condition, and regain their quality of life."

Peter Stein, CEO at Norgine, said, "Our collaboration with Innovacell is a major step forward in developing a truly innovative therapy in a disease area in which we have strong expertise.  Faecal incontinence is a common and distressing condition that may severely restrict patients' activities and through the development and marketing of ICEF15, we hope to offer a novel and long life lasting treatment option."

He added: "ICEF15 is a strong addition to our portfolio. Our approach to partnering is flexible and our efforts are always focused to find and work with partners who have complementary skills and a shared vision for improving healthcare. Partnering is a key priority for our long-term growth and success as an independent and leading pan-European specialty pharmaceutical company."

Financial terms are not disclosed.

Access full release http://www.norgine.com

Media Contacts

Isabelle Jouin, Norgine, Tel: +44(0)1895-453-643;  M: + 44(0)771-406-1327

Christian Loitz, wikopreventk GmbH; christian.loitz@wikopreventk.com; M : +43(0)650-7245825



'/>"/>
SOURCE Norgine B.V.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
3. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
4. Elsevier Appoints New President of Elsevier CPM Resource Center
5. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
6. Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
7. Guangzhous Sun Yat-sen University Cancer Center Debuts MOSAIQ in the Chinese Platform
8. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
9. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
10. Childrens National Medical Center Breaks MRI Speed Sound Barrier
11. Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in Gastroenterology Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading ... Word(TM) Online(TM), which enables sleep physicians to create and edit their interpretation reports. ... and provides a familiar interface that does not require additional training to use. ...
(Date:4/28/2017)... Grants Pass, OR (PRWEB) , ... April 28, ... ... Adetutu Ijose, http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and ... Kleyne Hour Power of Water, Global Climate Change and Your Health on Voice ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood ... to the labor and delivery team at Women’s Hospital at Renaissance in Edinburg for ... birth at the hospital and decide to donate. , “Women’s Hospital at Renaissance ...
(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
(Date:4/28/2017)... , ... April 28, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to ... to bookmark and read organized content on topics such as home care (generally) as ...
Breaking Medicine News(10 mins):